103028-32-6

Basic information

• Product Name: 6-broMo-8-Methoxyquinoline
• Synonyms: 6-broMo-8-Methoxyquinoline
• CAS NO: 103028-32-6
• Molecular Formula: C₁₀H₈BrNO
• Molecular Weight: 238.08062
• Mol File: 103028-32-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 70-80 °C(Press: 24 Torr)
• Appearance: /
• Density: 1.516±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.49±0.20(Predicted)
• CAS DataBase Reference: 6-broMo-8-Methoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-8-Methoxyquinoline(103028-32-6)
• EPA Substance Registry System: 6-broMo-8-Methoxyquinoline(103028-32-6)

Safety Data

• Hazardous Substances Data: 103028-32-6(Hazardous Substances Data)

Usage

Description

6-Bromo-8-Methoxyquinoline is a novel quinoline derivative that has been identified for its potential anticancer properties. It is a synthetic compound with a unique chemical structure that may contribute to its therapeutic effects.

Uses

Used in Anticancer Applications:
6-Bromo-8-Methoxyquinoline is used as an anticancer agent due to its potential to exhibit anticancer activity. As a quinoline derivative, it may interact with cellular targets and modulate various signaling pathways, thereby inhibiting tumor growth and progression. Further research and development are necessary to fully understand its mechanisms of action and optimize its therapeutic potential.
Used in Pharmaceutical Industry:
6-Bromo-8-Methoxyquinoline is used as a compound in the pharmaceutical industry for the development of new drugs targeting cancer. Its unique chemical structure and potential anticancer properties make it a promising candidate for further investigation and possible incorporation into novel drug formulations.

Upstream product

• 59557-91-4 4-bromo-2-methoxyaniline 
• 56-81-5 glycerol 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 67-56-1 methanol 
• 190843-73-3 6,8-dibromo-1,2,3,4-tetrahydroquinoline 
• 90-04-0 2-methoxy-phenylamine 

Downstream Products

• 139399-64-7 6-bromo-8-quinolinol 
• 834906-36-4 2,2-Dimethyl-propionic acid 6-{(S)-3-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-2-hydroxy-propyl}-quinolin-8-yl ester 
• 834906-32-0 1-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-3-[8-(tert-butyl-dimethyl-silanyloxy)-quinolin-6-yl]-propan-2-ol 
• 834906-34-2 6-[3-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-2-(tert-butyl-dimethyl-silanyloxy)-propyl]-quinolin-8-ol 
• 834906-29-5 2,2-Dimethyl-propionic acid 6-{(2R,4S,5R)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-quinolin-8-yl ester 
• 834906-35-3 2,2-dimethyl-propionic acid 6-[3-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-2-(tert-butyl-dimethyl-silanyloxy)-propyl]-quinolin-8-yl ester 
• 834906-33-1 6-[3-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-2-(tert-butyl-dimethyl-silanyloxy)-propyl]-8-(tert-butyl-dimethyl-silanyloxy)-quinoline 

Relevant articles and documents

Synthesis and structure-activity relationships study of α-aminophosphonate derivatives containing a quinoline moiety

Two series of α-aminophosphonate derivatives containing a quinoline moiety have been designed and synthesized by introducing bioactive quinoline scaffold to α-aminophosphonate. The in vitro cytotoxic activities of target compounds were first investigated against two human cancer cell lines including Eca109 and Huh7 by MTT assay. Results revealed that most of target compounds exhibited moderate to high antitumor activities against the tested cancer cell lines and some demonstrated more potent inhibitory activities compared with Sunitinib. Among them, compounds 4b2 and 4b4 containing methyl-substituted aniline group were found to be more active than Sunitinib against both of two cancer cell lines, with IC50 in the range of 2.26?μmol/L–7.46?μmol/L.

MACROCYCLIC COMPOUNDS

The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by excessive cellular proliferation such as cancer.

MCL-1 INHIBITORS AND METHODS OF USE THEREOF

Disclosed are Mcl-1 inhibitors, pharmaceutical compositions comprising the same and methods of using the same.